
Eli Lilly teams up with Chi-Med for Chinese sales of Elunate capsules
pharmafile | July 28, 2020 | News story | Manufacturing and Production, Sales and Marketing | Chi-Med, China, Eli Lilly
Eli Lilly Shanghai, an affiliate of the wider company, has enlisted the help of biopharma firm Hutchinson China MediTech, or Chi-Med, to commercialise its vascular endothelial growth factor receptor (VEGFR) 1/2/3 inhibitor therapy Elunate (fruquintinib capsules) in the Chinese market, it has emerged.
The partnership kicks off in earnest from 1 October this year, from which date Chi-Med will handle all medical detailing, promotion and local and regional marketing activities related to Elunate. Lilly retains exclusive commercialisation rights for the drug and with continue to consolidate sales made in China.
As part of the deal there will be no upfront payments, but both companies will share gross profits arising from successful sales targets in China, with Chi-Med eligible to receive an estimated total of between 70% and 80% of all Elunate sales in manufacturing costs, service payments, and royalties.
Chi-Med CEO Christian Hogg, CEO of Chi-Med and Julio Gay-Ger, President & General Manager of Lilly China, said in a joint statement: “After many years of constructive and successful collaboration, Lilly and Chi-Med believe that this agreement now establishes the optimal structure that will allow us to leverage the full resources of both companies to maximize the potential of Elunate in China.”
Matt Fellows
Related Content

Lilly opens fourth US Gateway Labs site
Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …

Lilly’s drug for early Alzheimer’s shows promising results
Eli Lilly (Lilly) has announced positive new data from the long-term extension of its phase …

Roche receives CE Mark for blood test to help rule out Alzheimer’s
Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in …






